Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Angiogenesis Modulators Market Status and Forecast (2016-2027)
  • 1.3.2 Global Angiogenesis Modulators Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Angiogenesis Modulators Supply by Company

• 2.1 Global Angiogenesis Modulators Sales Volume by Company
• 2.2 Global Angiogenesis Modulators Sales Value by Company
• 2.3 Global Angiogenesis Modulators Price by Company
• 2.4 Angiogenesis Modulators Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional Angiogenesis Modulators Market Status by Category

• 3.1 Angiogenesis Modulators Category Introduction
  • 3.1.1 Angiogenesis Inhibitors
  • 3.1.2 Angiogenesis Stimulators
  • 3.1.3 Angiogenin
  • 3.1.4 Others
• 3.2 Global Angiogenesis Modulators Market by Category
  • 3.2.1 Global Angiogenesis Modulators Sales Volume by Category (2016-2021)
  • 3.2.2 Global Angiogenesis Modulators Sales Value by Category (2016-2021)
  • 3.2.3 Global Angiogenesis Modulators Price by Category (2016-2021)
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Angiogenesis Modulators Market Status by End User/Segment

• 4.1 Angiogenesis Modulators Segment by End User/Segment
  • 4.1.1 Breast Cancer
  • 4.1.2 Colorectal Cancer
  • 4.1.3 Lung Cancer
  • 4.1.4 Prostate Cancer
  • 4.1.5 Others
• 4.2 Global Angiogenesis Modulators Market by End User/Segment
  • 4.2.1 Global Angiogenesis Modulators Sales Volume by End User/Segment (2016-2021)
  • 4.2.2 Global Angiogenesis Modulators Sales Value by End User/Segment (2016-2021)
  • 4.2.3 Global Angiogenesis Modulators Price by End User/Segment (2016-2021)
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Angiogenesis Modulators Market Status by Region

• 5.1 Global Angiogenesis Modulators Market by Region
  • 5.1.1 Global Angiogenesis Modulators Sales Volume by Region
  • 5.1.2 Global Angiogenesis Modulators Sales Value by Region
• 5.2 North America Angiogenesis Modulators Market Status
• 5.3 Europe Angiogenesis Modulators Market Status
• 5.4 Asia Pacific Angiogenesis Modulators Market Status
• 5.5 Central & South America Angiogenesis Modulators Market Status
• 5.6 Middle East & Africa Angiogenesis Modulators Market Status

6 North America Angiogenesis Modulators Market Status

• 6.1 North America Angiogenesis Modulators Market by Country
  • 6.1.1 North America Angiogenesis Modulators Sales Volume by Country (2016-2021)
  • 6.1.2 North America Angiogenesis Modulators Sales Value by Country (2016-2021)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Angiogenesis Modulators Market Status

• 7.1 Europe Angiogenesis Modulators Market by Country
  • 7.1.1 Europe Angiogenesis Modulators Sales Volume by Country (2016-2021)
  • 7.1.2 Europe Angiogenesis Modulators Sales Value by Country (2016-2021)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Angiogenesis Modulators Market Status

• 8.1 Asia Pacific Angiogenesis Modulators Market by Country
  • 8.1.1 Asia Pacific Angiogenesis Modulators Sales Volume by Country (2016-2021)
  • 8.1.2 Asia Pacific Angiogenesis Modulators Sales Value by Country (2016-2021)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Angiogenesis Modulators Market Status

• 9.1 Central & South America Angiogenesis Modulators Market by Country
  • 9.1.1 Central & South America Angiogenesis Modulators Sales Volume by Country (2016-2021)
  • 9.1.2 Central & South America Angiogenesis Modulators Sales Value by Country (2016-2021)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Angiogenesis Modulators Market Status

• 10.1 Middle East & Africa Angiogenesis Modulators Market by Country
  • 10.1.1 Middle East & Africa Angiogenesis Modulators Sales Volume by Country (2016-2021)
  • 10.1.2 Middle East & Africa Angiogenesis Modulators Sales Value by Country (2016-2021)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 Angiogenesis Modulators Manufacturing Cost Analysis
• 11.5 Angiogenesis Modulators Sales Channel and Distributors Analysis
  • 11.5.1 Angiogenesis Modulators Sales Channel
  • 11.5.2 Angiogenesis Modulators Distributors
• 11.6 Angiogenesis Modulators Downstream Major Buyers

12 Global Angiogenesis Modulators Market Forecast by Category and by End User/Segment

• 12.1 Global Angiogenesis Modulators Sales Volume and Sales Value Forecast (2022-2027)
• 12.2 Global Angiogenesis Modulators Forecast by Category
  • 12.2.1 Global Angiogenesis Modulators Sales Volume Forecast by Category
  • 12.2.2 Global Angiogenesis Modulators Sales Value Forecast by Category
  • 12.2.3 Global Angiogenesis Modulators Price Forecast by Category
• 12.3 Global Angiogenesis Modulators Forecast by End User/Segment
  • 12.3.1 Global Angiogenesis Modulators Sales Volume Forecast by End User/Segment
  • 12.3.2 Global Angiogenesis Modulators Sales Value Forecast by End User/Segment
  • 12.3.3 Global Angiogenesis Modulators Price Forecast by End User/Segment

13 Global Angiogenesis Modulators Market Forecast by Region/Country

• 13.1 Global Angiogenesis Modulators Market Forecast by Region (2022-2027)
  • 13.1.1 Global Angiogenesis Modulators Sales Volume Forecast by Region (2022-2027)
  • 13.1.2 Global Angiogenesis Modulators Sales Value Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 GlaxoSmithKline plc (UK)
  • 14.1.1 Company Information
  • 14.1.2 Angiogenesis Modulators Product Introduction
  • 14.1.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Genentech, Inc. (USA)
  • 14.2.1 Company Information
  • 14.2.2 Angiogenesis Modulators Product Introduction
  • 14.2.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 F.Hoffmann-La Roche AG (Switzerland)
  • 14.3.1 Company Information
  • 14.3.2 Angiogenesis Modulators Product Introduction
  • 14.3.3 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Eli Lilly and Company (USA)
  • 14.4.1 Company Information
  • 14.4.2 Angiogenesis Modulators Product Introduction
  • 14.4.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Eisai (Japan)
  • 14.5.1 Company Information
  • 14.5.2 Angiogenesis Modulators Product Introduction
  • 14.5.3 Eisai (Japan) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Celgene Corporation (USA)
  • 14.6.1 Company Information
  • 14.6.2 Angiogenesis Modulators Product Introduction
  • 14.6.3 Celgene Corporation (USA) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 CASI Pharmaceuticals, Inc. (USA)
  • 14.7.1 Company Information
  • 14.7.2 Angiogenesis Modulators Product Introduction
  • 14.7.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Bionomics Ltd. (Australia)
  • 14.8.1 Company Information
  • 14.8.2 Angiogenesis Modulators Product Introduction
  • 14.8.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Bayer Pharma AG (Germany)
  • 14.9.1 Company Information
  • 14.9.2 Angiogenesis Modulators Product Introduction
  • 14.9.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 AstraZeneca plc (UK)
  • 14.10.1 Company Information
  • 14.10.2 Angiogenesis Modulators Product Introduction
  • 14.10.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Amgen, Inc. (USA)

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Angiogenesis Modulators market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Angiogenesis Modulators market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others

Segmented by End User/Segment
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
GlaxoSmithKline plc (UK)
Genentech, Inc. (USA)
F.Hoffmann-La Roche AG (Switzerland)
Eli Lilly and Company (USA)
Eisai (Japan)
Celgene Corporation (USA)
CASI Pharmaceuticals, Inc. (USA)
Bionomics Ltd. (Australia)
Bayer Pharma AG (Germany)
AstraZeneca plc (UK)
Amgen, Inc. (USA)